Siranbio
Latest round
- Series A
Last raised
- Aug 2026
Total raised
- Undisclosed
Investors
- 8
About Siranbio
, trading as Siranbio, is engaged in the research and development of siRNA therapeutics. The company specializes in developing innovative small interfering RNA (siRNA) drugs to address unmet clinical needs across various disease areas, including viral infections, cardiovascular and metabolic disorders, autoimmune diseases, and central nervous system conditions. Key product lines include the SA1211 dual-target siRNA, aimed at achieving functional cures for hepatitis B, and the lead product SA030, a weight reduction siRNA drug. The company's revenue is generated by sales of their innovative therapies, positioned as solutions in the biopharmaceutical sector.
Who invested in Siranbio
8 investors across 1 round
See all investors in Siranbio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 20, 2026
Amount
Undisclosed
Investors
Questions about Siranbio
Who invested in Siranbio?
Siranbio has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Siranbio raised?
Siranbio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Siranbio last raise money?
Siranbio's most recent round on record is a Series A, in Aug 2026.
What does Siranbio do?
, trading as Siranbio, is engaged in the research and development of siRNA therapeutics.
Where is Siranbio headquartered?
Siranbio is headquartered in Suzhou, China.
Which VCs invest in companies like Siranbio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Siranbio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Siranbio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.